Angela Dziedzic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/460618/publications.pdf Version: 2024-02-01



ANCELA DZIEDZIC

#	Article	IF	CITATIONS
1	Variations in the Gene Expression Profile in Atherosclerotic Patients with Non-Fatal ACS: A Preliminary Study. International Journal of Molecular Sciences, 2022, 23, 5017.	4.1	1
2	The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 1804.	4.1	24
3	miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. International Journal of Molecular Sciences, 2021, 22, 4332.	4.1	33
4	The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y12 Pathway in Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 6572.	4.1	6
5	Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic's) Tj ETQq1	1 0.7843 4.1	14 rgBT /0v 16
6	Unusual Bioactive Compounds with Antioxidant Properties in Adjuvant Therapy Supporting Cognition Impairment in Age-Related Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 10707.	4.1	8
7	Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review. International Journal of Molecular Sciences, 2021, 22, 11887.	4.1	13
8	Increased Pro-Thrombotic Platelet Activity Associated with Thrombin/PAR1-Dependent Pathway Disorder in Patients with Secondary Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 7722.	4.1	11
9	Oxidative Damage of Blood Platelets Correlates with the Degree of Psychophysical Disability in Secondary Progressive Multiple Sclerosis. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-12.	4.0	7
10	Metformin as a Potential Agent in the Treatment of Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 5957.	4.1	31
11	The GPR17 Receptor—A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 1852.	4.1	16
12	A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients, 2019, 11, 1528.	4.1	65
13	Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients. Journal of Cellular and Molecular Medicine, 2019, 23, 3476-3482.	3.6	21
14	Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis. Cells, 2019, 8, 110.	4.1	29
15	Interactions between platelets and leukocytes in pathogenesis of multiple sclerosis. Advances in Clinical and Experimental Medicine, 2019, 28, 277-285.	1.4	14
16	Flavonolignans reduce the response of blood platelet to collagen. International Journal of Biological Macromolecules, 2018, 106, 878-884.	7.5	27
17	Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets. Molecules, 2018, 23, 374.	3.8	15
18	Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes. Nutrients, 2017, 9, 1022.	4.1	12

#	Article	IF	CITATIONS
19	Editorial. VI PhD Students National Conference of Life Sciences "BioOpen― Acta Universitatis Lodziensis Folia Biologica Et Oecologica, 0, 17, 5-6.	1.0	0